Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer

Journal of Pathology

Volumn 195, Issue 2, 2001, Pages 236-243

  Fox, Stephen B ^a,b,c,d   Taylor, Marian ^a   Grøndahl Hansen, Jan ^b   Kakolyris, Stelios ^a   Gatter, Kevin C ^a   Harris, Adrian L ^a  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c FINSEN LABORATORY   (Denmark)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Breast cancer; Plasminogen activator; Prognosis; Thymidine phosphorylase; Tumour angiogenesis; Urokinase; Vascular remodelling

Indexed keywords

ANGIOGENIC FACTOR; EPITOPE; LH39 PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

AGE; ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER THERAPY; CAPILLARY; CELL INVASION; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOSOL; DENSITY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; METASTASIS; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL; TUMOR VASCULARIZATION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034812857     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.931     Document Type: Article

References (65)

1. Plasminogen activators, tissue degradation, and cancer
2. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion
3. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
4. Physiological mechanisms for metalloproteinase activation
5. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity
6. The urokinase-type plasminogen activator system in cancer metastasis: A review
7. What is the evidence that tumours are angiogenesis dependent?
8. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis
9. Upregulation of urokinase receptor expression on migrating endothelial cells
10. Plasminogen activators (urokinase) mediate neovascularization: Possible role in tumor angiogenesis
11. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
12. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
13. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
14. Tumour angiogenesis and prognosis
15. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
16. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
17. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
18. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
19. Vascular remodelling in breast cancer angiogenesis assessed by LH39 basement membrane antigen and CD31
20. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
21. Grading of invasive carcinoma of the breast
22. JC70: A new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections
23. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
24. Method for the quantative morphological analysis of tissues
25. Tumor angiogenesis in node-negative breast carcinomas - Relationship with epidermal growth factor receptor, estrogen receptor, and survival
26. The distribution of LH39 basement membrane epitope in the tumour stroma of oral squamous cell carcinomas
27. Novel lamina lucida component of epithelial and endothelial basement membranes detected by LH39 monoclonal antibody
28. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39
29. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: Correlation with p53 and angiogenic factor expression
30. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study
31. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
32. Relationship of elevated tumour thymidine phosphorylase in node positive breast carcinomas to the effects of adjuvant CMF
33. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours
34. Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease
35. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
36. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
37. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
38. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors
39. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients
40. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
41. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer
42. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis
43. Urokinase and macrophages in tumour angiogenesis
44. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels
45. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues
46. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer
47. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma
48. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
49. Combined over-expression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues
50. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
51. Thymidine phosphorylase is angiogenic and promotes tumor growth
52. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
53. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression
54. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition
55. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway
56. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
57. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma
58. Prognostic value of urokinase plasminogen activator in primary breast carcinoma: Comparison of two immunoassay methods
59. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients
60. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
61. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer
62. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer
63. Urokinase-type plasminogen activator antigen and early relapse in breast cancer
64. Identification of the urokinase receptor as an adhesion receptor for vitronectin
65. Vitronectin binding to urokinase receptor in human breast cancer